Melatonin and cancer: Current knowledge and its application to oral cavity tumours

Journal of Oral Pathology and Medicine

Volumn 40, Issue 8, 2011, Pages 593-597

  Cutando, Antonio ^a   Aneiros Fernández, José ^b   Aneiros Cachaza, José ^b   Arias Santiago, Salvador ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Cancer; MT1 melatonin receptor; MT2 melatonin receptor; MT3 melatonin receptor; Oral cavity; RZR ROR melatonin receptor

Indexed keywords

ANTIOXIDANT; CALCIUM; CALMODULIN; CELL PROTEIN; G PROTEIN COUPLED RECEPTOR; GLUTATHIONE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PROTEIN P53; SCAVENGER;

CALCIUM BINDING; CANCER GROWTH; CIRCADIAN RHYTHM; COCHRANE LIBRARY; DISEASE COURSE; DNA METHYLATION; ENZYME REGULATION; GLUTATHIONE METABOLISM; HORMONE ACTION; HORMONE RELEASE; MEDLINE; MOUTH TUMOR; ORAL SURGERY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SLEEP DEPRIVATION; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANTIOXIDANTS; CARCINOMA; HUMANS; MELATONIN; MOUTH NEOPLASMS; RECEPTORS, MELATONIN;

EID: 79953862700     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.01002.x     Document Type: Review

References (64)

1. McCord CP, Allen FB. Evidences associating pineal gland function with alterations in pigmentation. J Exp Zool 1917; 23: 207-24.
2. Lerner AB, Case JD, Takahashi Y. Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 1960; 235: 1992-7.
3. Reiter RJ. The mammalian pineal gland: structure and function. Am J Anat 1981; 162: 287-313.
4. Claustrat B, Brun J, Chazot G. The basic physiology and pathophysiology of melatonin. Sleep Med Rev 2005; 9: 11-24.
5. Sugden D, Klein DC. A cholera toxin substrate regulates cyclic GMP content of rat pinealocytes. J Biol Chem 1987; 262: 7447-50.
6. Reiter RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12: 151-80.
7. Klein DC, Moore RY. Pineal N-acetyltransferase and hydroxyindole-O-methyltransferase: control by the retinohypothalamic tract and the suprachiasmatic nucleus. Brain Res 1979; 174: 245-62.
8. Brainard GC, Hanifin JP, Greeson JM, et al. Action spectrum for melatonin regulation in humans: evidence for a novel circadian photoreceptor. J Neurosci 2001; 21: 6405-12.
9. Moore RY. Neural control of the pineal gland. Behav Brain Res 1996; 73: 125-30.
10. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273-85. Available at: (accessed on 10 May, 2010).
11. Jarzynka MJ, Passey DK, Johnson DA, et al. Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms in vitro and in vivo evidence. J Pineal Res 2009; 46: 161-71.
12. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides and other pineal transmitters. Pharmacol Rev 2003; 55: 325-95.
13. Arendt J. Melatonin, circadian rhythms and sleep. N Engl J Med 2000; 343: 1114-6.
14. Cajochen C, Kraüchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003; 15: 432-7.
15. Reiter RJ, Tan DX, Manchester LC, et al. Melatonin and reproduction revisited. Biol Reprod 2009; 81: 445-56.
16. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and others indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47: 109-26.
17. Tan DX, Manchester LC, Hardeland R, et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003; 34: 75-8.
18. Benot S, Goberna R, Reiter RJ, et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 1999; 27: 59-64.
19. Siu AW, Maldonado M, Sanchez-Hidalgo M, et al. Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res 2006; 40: 101-9.
20. Brzozowski T, Konturek PC, Zwirska-Korczala K, et al. Importance of the pineal gland, endogenous prostaglandins and sensory nerves in the gastroprotective actions of central and peripheral melatonin against stress-induced damage. J Pineal Res 2005; 39: 375-85.
21. Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Cri Rev Biochem Mol Biol 2009; 44: 175-200.
22. Laakso ML, Porkka-Heiskanen T, Alila A, et al. Correlation between salivary and serum melatonin: dependence on serum melatonin levels. J Pineal Res 1990; 9: 39-50.
23. Tan DX, Manchester LC, Reiter LC, et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of melatonin interaction with hydroxyl radicals. Biochem Biophys Res Commun 1998; 253: 614-20.
24. Sack RL, Lewy RL, Vollmer RM, Singer CM. Human melatonin production decreases with age. J Pineal Res 1986; 3: 379-88.
25. Peyrot F, Ducrocq C. Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J Pineal Res 2008; 45: 235-46.
26. Pozo D, Reiter RJ, Calvo JR, Guerrero JM. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. J Cell Biochem 1997; 65: 430-42.
27. Garcia-Maurino S, Pozo D, Calvo JR, Guerrero JM. Correlation between nuclear melatonin reception expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. J Pineal Res 2000; 29: 129-37.
28. Dubocovich M, Markowska M. Functional MT1 and MT2 melatonin receptor in mammals. Endocrine 2005; 27: 101-10.
29. Tan DX, Chen LD, Poeggeler B, et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-63.
30. Reiter RJ, Tan DX, Osuna C, Gitto E. Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci 2000; 7: 444-58.
31. Urata Y, Honma S, Goto S, et al. Melatonin induces gamma-glutymlcysteine synthetase mediated by activator protei-1 in human vascular endothelial cells. Free Radic Biol Med 1999; 27: 838-49.
32. Tan DX, Reiter RJ, Manchester RL, et al. Chemical and physical properties and potential mechanisms: melatonin as a broad-spectrum antioxidant and free radical scavenger. Curr Top Med Chem 2002; 2: 181-98.
33. Acuña-Castroviejo D, Martin M, Macias M, et al. Melatonin, mitochondria and cellular bioenergetics. J Pineal Res 2001; 30: 65-74.
34. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008; 44: 26-40.
35. Pappolla MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm 2000; 107: 203-31.
36. Antolin I, Mayo JC, Sainz RM, et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002; 943: 163-73.
37. Gitto E, Karbownik M, Reiter RJ, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001; 50: 756-60.
38. Fulia F, Gitto E, Cuzzocrea S, et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res 2001; 31: 343-9.
39. Bangha E, Elsner P, Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5 methoxytryptamine). A dose response study. Arch Dermatol Res 1996; 288: 522-6.
40. Herrera J, Nava M, Romero F, Rodriquez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-7.
41. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for late dyskinesia: a double-blind, placebo-controlled, cross-over study. Arch Gen Psychiatry 2001; 58: 1049-52.
42. Reiter RJ, Tan DX, Sainz RM, et al. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-321.
43. Cutando A, Arana C, Gomez G, et al. Local application of melatonin into alveolar sockets of beagle dogs reduces tooth removal-induced oxidative stress. J Periodontol 2007; 78: 576-83.
44. Sanchez-Barcelo EJ, Cos S, Mediavilla D, et al. Melatonin-estrogen interactions in breast cancer. J Pineal Res 2005; 38: 217-22.
45. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, et al. Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J Neuroimmunol 1998; 92: 76-84.
46. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005; 39: 99-104.
47. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front Biosci 2003; 8: 1093-108.
48. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre RM et al. IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media, 1998; 187-93.
49. Jockers R, Maurice P, Boutin JA, Delangre P. Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 2008; 154: 1182-95.
50. Reppert SM, Weaver DR, Ebisawa T, et al. Cloning of melatonin-related receptor from human pituitary. FEBS Lett 1996; 386: 219-24.
51. Ivanova EA, Bechtold DA, Dupré SM, et al. Altered metabolism in the melatonin-realted receptor(GPR50) knock out Mouse. Am J Physiol Endocrinol Metab 2007; 294: E176-82.
52. Duncan MJ, Takahashi JS, Dubocovich ML. 2[125]Iodomelatonin binding sites in hamster brain membranes: pharmacological characteristiques and regional distribution. Endocrinology, 1998; 122: 1825-33.
53. Calamini B, Santarsiero BD, Boutin JA, Resacar AD. Kinetic, thermodynamic and X-ray structural insights on the interaction of melatonin and analogs with quinone reductase. Biochem J 2008; 413: 81-91.
54. Mailliet F, Ferry G, Vella F, et al. Characterization of melatoninergic MT3 binding site on the NRH: quinone oxidoreductasa 2 enzyme. Biochem Pharmacol 2005; 71: 74-88.
55. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 2005; 27: 179-88.
56. Mirick D, Scott D. Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev 2008; 17: 3306-13.
57. Cos S, Mediavilla MD, Fernandez R, et al. Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro?. J Pineal Res 2002; 32: 90-6.
58. Czeisler CA, Klerman EB. Circadian and sleep-dependent regulation of hormone release in humans. Recent Prog Horm Res 1999; 54: 97-130.
59. Flynn-Evans EE, Stevens RG, Tabandeh H, et al. Total visual blindness is protective against breast cancer. Cancer Causes Control 2009; 20: 1753-6.
60. Kantermann T, Roenneberg T. Is light-at-night a health risk factor or a health risk predictor? Chronobiol Int 2009; 26: 1069-74.
61. Martín-Renedo J, Mauriz JL, Jorquera F, et al. Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J Pineal Res 2008; 45: 532-40.
62. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 3: clinico-pathological applications. Oral Oncol 2000; 36: 404-13.
63. Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. Lancet Oncol 2006; 7: 77-82.
64. Nakamura E, Kozaki K, Tsuda H, et al. Frequent silencing of a putative tumour suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous-cell carcinoma. Cancer Sci 2008; 99: 1390-400.